Supplemental Figure 7: Macrophage subtypes are unaffected by treatment in patients in SR-1. (A) Baseline and on-treatment biopsies from patients (n = 6 paired samples) in the SR-1 trial were analyzed by multiplex immunofluorescence using the indicated antibodies. Representative image of the macrophage panel is shown. (B) Densities of total macrophages (CD68⁺ or CD163⁺ cells). (C) Densities of M1 polarized macrophages (CD86⁺IRF5⁺). (D) Densities of M2 polarized macrophages (CD206⁺CD163⁺).
No takes yet. Share an insight, caveat, or question.
Oberstein et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: